Show simple item record

dc.contributor.authorvan Os, Elise Anne
dc.contributor.authorCools, Laura
dc.contributor.authorEysackers, Nathalie
dc.contributor.authorSzafranska, Karolina
dc.contributor.authorSmout, Ayla
dc.contributor.authorVerhulst, Stefaan
dc.contributor.authorReynaert, Hendrik
dc.contributor.authorMcCourt, Peter Anthony
dc.contributor.authorMannaerts, Inge
dc.contributor.authorvan Grunsven, Leo A.
dc.date.accessioned2023-01-16T06:42:54Z
dc.date.available2023-01-16T06:42:54Z
dc.date.issued2022-09-28
dc.description.abstractChronic liver disease can lead to liver fibrosis and ultimately cirrhosis, which is a significant health burden and a major cause of death worldwide. Reliable in vitro models are lacking and thus mono-cultures of cell lines are still used to study liver disease and evaluate candidate anti-fibrotic drugs. We established functional multicellular liver spheroid (MCLS) cultures using primary mouse hepatocytes, hepatic stellate cells, liver sinusoidal endothelial cells and Kupffer cells. Cell-aggregation and spheroid formation was enhanced with 96-well U-bottom plates generating over ±700 spheroids from one mouse. Extensive characterization showed that MCLS cultures contain functional hepatocytes, quiescent stellate cells, fenestrated sinusoidal endothelium and responsive Kupffer cells that can be maintained for 17 days. MCLS cultures display a fibrotic response upon chronic exposure to acetaminophen, and present steatosis and fibrosis when challenged with free fatty acid and lipopolysaccharides, reminiscent of non-alcoholic fatty liver disease (NAFLD) stages. Treatment of MCLS cultures with potential anti-NAFLD drugs such as Elafibranor, Lanifibranor, Pioglitazone and Obeticholic acid shows that all can inhibit steatosis, but only Elafibranor and especially Lanifibranor inhibit fibrosis. Therefore, primary mouse MCLS cultures can be used to model acute and chronic liver disease and are suitable for the assessment of anti-NAFLD drugs.en_US
dc.identifier.citationvan Os, Cools, Eysackers, Szafranska, Smout, Verhulst, Reynaert, McCourt, Mannaerts, van Grunsven. Modelling fatty liver disease with mouse liver-derived multicellular spheroids. Biomaterials. 2022;290en_US
dc.identifier.cristinIDFRIDAID 2077120
dc.identifier.doi10.1016/j.biomaterials.2022.121817
dc.identifier.issn0142-9612
dc.identifier.issn1878-5905
dc.identifier.urihttps://hdl.handle.net/10037/28225
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.journalBiomaterials
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/766181/EU/Super-resolution optical microscopy of nanosized pore dynamics in endothelial cells/DeLiver/en_US
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)en_US
dc.titleModelling fatty liver disease with mouse liver-derived multicellular spheroidsen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)